Adicet Bio, Inc. announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2022 Oncology Conference taking place virtually on February 9-11, 2022.
MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2022 Oncology Conference taking place virtually on February 9-11, 2022.
Details of the event are as follows:
Date: Wednesday, February 9, 2022
Time: 11:30 am ET
A live audio webcast of the fireside chat can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220201006166/en/
Adicet Bio., Inc.
Investor Contacts
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com
Source: Adicet Bio, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20220201006166/en
